Veterinary Intravenous (IV) Solutions Market – By Product (Isotonic Crystalloids, Dextrose, Synthetic Colloids), Indication (Diabetic Ketoacidosis, Pancreatitis, Anthrax), Animal Type (Companion, Production), End-user, Global Forecast 2024 – 2032

Veterinary Intravenous Solutions Market Size

Veterinary Intravenous Solutions Market accounted for USD 1.5 billion in 2023 and is anticipated to experience growth at 8% CAGR between 2024 and 2032. Advancements in veterinary medicine have greatly boosted the market. New IV fluid delivery systems, like specialized infusion pumps and fluid monitors, have made IV solution administration more efficient and safer. These technologies ensure accurate fluid delivery and reduce complications, supporting market growth.
 

Another key driver is the increase in pet adoption and spending on pet healthcare. As more people adopt pets, the demand for veterinary care, including IV therapy for health issues, surgeries, and critical care, grows. This trend shows a societal shift towards investing more in pet health?.
 

Veterinary IV solutions are sterile liquids given directly into an animal's bloodstream to treat medical conditions. They help restore hydration, balance electrolytes, and provide nutrients. These solutions are crucial for managing dehydration, shock, and during surgeries. Types include isotonic crystalloids, synthetic colloids, natural colloids, dextrose solutions, and parenteral nutrition. They are vital for maintaining blood volume, tissue perfusion, and supporting metabolic functions in both routine and critical care?.
 

Veterinary Intravenous Solutions Market Trends

• The rising adoption of pet insurance is significantly driving the growth of the veterinary intravenous (IV) solutions market. As pet ownership increases, more pet owners are recognizing the importance of having insurance to cover unexpected veterinary costs.
   
• For instance, according to the North American Pet Health Insurance Association (NAPHIA) 2024 State of the Industry (SOI) Report shows that over 6.25 million pets insured across North America (a 20.9% increase from the 5.17 million pets insured in 2022).
   
• Pet insurance helps mitigate the financial burden of veterinary care, encouraging pet owners to seek comprehensive treatments, including the use of intravenous (IV) solutions for their pets. With insured pets, owners are more likely to afford advanced treatments, which include IV therapies necessary for various conditions such as dehydration, surgery recovery, and chronic illnesses.
   

Veterinary Intravenous Solutions Market Analysis

Based on product, the market is segmented into isotonic crystalloids, dextrose solutions, synthetic colloids, natural colloids, and parenteral nutrition. The isotonic crystalloids segment dominated the market with 43.5% of market share in 2023.

• Isotonic crystalloids dominate the veterinary market, finding extensive application in routine procedures like surgery, anesthesia, and emergency care.
   
• Designed to closely match the osmolarity of animals' blood, isotonic crystalloids are not only safe for intravenous use but also exhibit high tolerance. This inherent compatibility minimizes the chances of adverse reactions, rendering them versatile across different species and medical scenarios. Consequently, their physiological harmony with animals further propels the segment growth.
   

Based on indication, the veterinary intravenous solutions market is categorized into diabetic ketoacidosis, pancreatitis, anthrax, chronic kidney disease, nutritional support, and other indications. The diabetic ketoacidosis segment held majority of market share and captured revenue of USD 442.7 million in 2023.
 

• The incidence of diabetes, particularly in dogs and cats, has been increasing. According to the American Veterinary Medical Association, approximately 1 in 300 dogs and 1 in 230 cats will develop diabetes during their lifetime.
   
• Diabetic ketoacidosis (DKA), a severe complication requiring immediate medical attention, often necessitates intensive fluid therapy with IV solutions for effective management. This condition underscores the critical need for prompt veterinary intervention.
   
• Furthermore, heightened awareness among pet owners and veterinarians about the signs and early diagnosis of diabetes and its complications has led to more frequent veterinary visits. This proactive approach facilitates early intervention, thereby increasing the use of IV solutions to manage conditions such as DKA.
   
• Such aforementioned factors contribute to the highest growth of diabetic ketoacidosis segment.
   

Based on animal type, the VI solutions market is classified into companion animals and production animals. The companion animals segment dominated the market and is poised to grow at 7.6% CAGR over the forecast timeframe.
 

• There is a substantial and growing number of companion animals, such as dogs and cats, owned by households worldwide. Pet owners are increasingly willing to spend more on the healthcare and well-being of their pets, leading to a higher demand for veterinary services, including IV therapy.
   
• Additionally, the increasing adoption of pet insurance also supports the companion animal segment's dominance in the market. Insurance coverage makes it more affordable for pet owners to pursue extensive treatments, including those requiring IV solutions, thereby boosting the market share of this segment.
   

Based on end-user, the veterinary intravenous solutions market is divided into veterinary hospitals & clinics, research institutes, and other end-users. The veterinary hospitals & clinics segment in 2023 accounted for significant market position and is predicted to reach USD 1.7 billion by 2032.
 

• These facilities generally see a higher volume of patients compared to other veterinary care providers. The increased patient load means a greater number of animals requiring IV therapy for various treatments, contributing to the segment’s significant market share.
   
• They are often equipped with advanced medical equipment and staffed by trained professionals capable of administering and monitoring IV therapy. This capability allows them to treat a variety of conditions effectively, increasing the utilization of IV solutions? and thereby driving the growth of veterinary hospitals & clinics segment.
   

North America veterinary intravenous solutions market was valued at USD 626.8 million in 2023 and is predicted to reach USD 1.2 billion in 2032 with 7.9% of CAGR.
 

• Chronic diseases such as diabetes, kidney disease, and cancer are becoming more common in pets. These conditions often require intensive management, including the use of IV solutions for hydration, medication administration, and nutritional support. The rising prevalence of such conditions significantly boosts the growth of market in North America.
   

In 2023, the U.S. veterinary intravenous solutions market accounted for USD 577.9 million and is expected to grow at 7.8% from 2024 - 2032.
 

• Pet ownership in the U.S. has seen a significant rise, with pets increasingly being viewed as family members. According to the 2023-2024 National Pet Owners Survey by the American Pet Products Association (APPA), 66% of U.S. households, or 86.9 million homes, now own a pet.
   
• This trend has resulted in increased spending on pet healthcare, including advanced treatments such as intravenous (IV) therapy.
   
• The commitment of pet owners to invest in their pets' health and well-being fuels the demand for veterinary IV solutions. For instance, the APPA reported that spending on pet care in the U.S. reached USD 136.8 billion in 2022, demonstrating a consistent rise in investment in pet health.
   

China veterinary intravenous solutions market is poised to showcase growth during the coming years.
 

• The number of veterinary clinics and hospitals in China is expanding, particularly in urban areas. These facilities are better equipped to provide advanced medical care, including IV therapy. The growth in veterinary infrastructure is expected to drive the growth of market.
   

India is expected to significantly grow in the global veterinary intravenous solutions market.
 

• India boasts a broad and varied livestock sector encompassing cattle, poultry, and aquaculture, highlighting the critical demand for veterinary healthcare, such as intravenous solutions, to uphold livestock health and productivity.
   
• Additionally, India continues to enhance its veterinary healthcare infrastructure, with increased availability of superior facilities and trained professionals, thereby stimulating demand for veterinary products. Thus, these factors are expected to drive the growth of India in global market.
   

Veterinary Intravenous Solutions Market Share

The VI solutions industry is characterized by a diverse competitive landscape, with key players vying for market share through product innovation, strategic partnerships, and geographical expansions. Companies such as Zoetis Inc., B. Braun, Hospira, and Merck & Co., Inc. are among the leading market participants, leveraging extensive product portfolios and strong distribution networks to maintain their competitive edge. These companies focus on continuous research and development to introduce novel products catering to specific veterinary healthcare needs.
 

Veterinary Intravenous Solutions Companies

Prominent players operating in the veterinary intravenous (IV) solutions industry include:

• B. Braun Melsungen AG
• Ceva Santé Animale
• Dechra Pharmaceuticals plc
• Elanco Animal Health
• Fresenius Kabi
• Hospira (Pfizer Inc.)
• Jorgensen Laboratories, LLC
• Merck & Co. Inc.
• Sykes Vet International Pty Ltd.
• Zoetis, Inc.
   

Veterinary Intravenous Solutions Industry News:

• In January 2023, Merck completed acquisition of Imago BioSciences, Inc. This strategic acquisition helped the enhance capabilities and broaden its market reach in veterinary healthcare and related sectors.
   

The veterinary intravenous solutions market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Isotonic crystalloids
• Dextrose solutions
• Synthetic colloids
• Natural colloids
• Parenteral nutrition

Market, By Indication

• Diabetic ketoacidosis
• Pancreatitis
• Anthrax
• Chronic kidney disease
• Nutritional support
• Other indications

Market, By Animal Type

• Companion animals
• Production animals

Market, By End-user

• Veterinary hospitals & clinics
• Research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa